Neogenomics, Inc.
NEO
$10.10
-$0.44-4.18%
| Weiss Ratings | NEO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | NEO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | NEO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.38 | |||
| Price History | NEO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -2.88% | |||
| 30-Day Total Return | -31.11% | |||
| 60-Day Total Return | -43.13% | |||
| 90-Day Total Return | -22.61% | |||
| Year to Date Total Return | -38.75% | |||
| 1-Year Total Return | -36.72% | |||
| 2-Year Total Return | -44.29% | |||
| 3-Year Total Return | -43.95% | |||
| 5-Year Total Return | -63.10% | |||
| 52-Week High % Change | -44.86% | |||
| 52-Week Low % Change | 17.37% | |||
| Price | NEO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $19.12 | |||
| 52-Week Low Price | $8.98 | |||
| 52-Week Low Price (Date) | Mar 04, 2025 | |||
| 52-Week High Price (Date) | Jan 08, 2025 | |||
| Valuation | NEO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 1.35B | |||
| Enterprise Value | 1.57B | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.63 | |||
| Earnings Per Share Growth | -11.70% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 2.03 | |||
| Price/Book (Q) | 1.50 | |||
| Enterprise Value/Revenue (TTM) | 2.38 | |||
| Price | $10.10 | |||
| Enterprise Value/EBITDA (TTM) | -262.47 | |||
| Enterprise Value/EBIT | -20.02 | |||
| Market Cap Category | Small Cap | |||
| Dividends and Shares | NEO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 127.16M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | NEO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 239 768 0600 | |||
| Address | 9490 NeoGenomics Way Fort Myers, FL 33912 | |||
| Website | www.neogenomics.com | |||
| Country | United States | |||
| Year Founded | 2001 | |||
| Profitability | NEO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -11.88% | |||
| Profit Margin | -11.91% | |||
| Management Effectiveness | NEO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -2.96% | |||
| Return on Equity | -- | |||
| Income Statement | NEO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 660.57M | |||
| Total Revenue (TTM) | 660.57M | |||
| Revenue Per Share | $5.19 | |||
| Gross Profit (TTM) | 290.10M | |||
| EBITDA (TTM) | -5.99M | |||
| EBIT (TTM) | -78.54M | |||
| Net Income (TTM) | -78.73M | |||
| Net Income Avl. to Common (TTM) | -78.73M | |||
| Total Revenue Growth (Q YOY) | 10.57% | |||
| Earnings Growth (Q YOY) | -6.97% | |||
| EPS Diluted (TTM) | -0.63 | |||
| EPS Diluted Growth (Q YOY) | -5.89% | |||
| Balance Sheet | NEO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 386.84M | |||
| Cash Per Share (Q) | $3.04 | |||
| Total Current Assets (Q) | 596.02M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 902.34M | |||
| Current Ratio (Q) | 1.979 | |||
| Book Value Per Share (Q) | $7.04 | |||
| Total Assets (Q) | 1.64B | |||
| Total Current Liabilities (Q) | 301.24M | |||
| Total Debt (Q) | 605.33M | |||
| Total Liabilities (Q) | 735.70M | |||
| Total Common Equity (Q) | 902.34M | |||
| Cash Flow | NEO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 12.86M | |||
| Cash from Financing (TTM) | 4.65M | |||
| Net Change in Cash (TTM) | 24.52M | |||
| Levered Free Cash Flow (TTM) | -6.49M | |||
| Cash from Operations (TTM) | 7.02M | |||
